Maryam Shirmohammadi

Maryam Shirmohammadi

Auto-generated profile, based on publicly available information

Maryam Shirmohammadi

Student Research Committee, Faculty of Medicine, Qom University of Medical Sciences, Qom, Iran

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Case Reports in Rheumatology
Verified
Journal Article
Open access
KJKimia Jazi
Kimia Jazi
MRMahnaz Rahimi
Mahnaz Rahimi
FHFatemeh Hasani
Fatemeh Hasani
MSMaryam Shirmohammadi
Maryam Shirmohammadi
MMMaryam Masoumi
Maryam Masoumi
The only way to mitigate the spread of coronavirus disease 2019 (COVID‐19) pandemic was vaccines. While effective in decreasing the rate and severity of the disease, there also have been considerable adverse events. Since the birth of vaccines, adverse reactions accompanied the immunity, and COVID‐19 vaccines are no exceptions. This is a report about a 52‐year‐old female patient who presented with bilateral redness of the eyes, with normal bilateral visual acuity, postbooster dose of the Sinopharm COVID‐19 vaccine. She had no significant past history of any disease or any similar reactions after previous doses. All her physical examinations were normal. Ophthalmic examination disclosed diffuse erythema, and mild scleral edema consistent with bilateral anterior diffused scleritis with negative phenylephrine test. Thereafter, with a course of tapering doses of prednisolone (30 mg at the onset) combined with azathioprine (100 mg/day), over a 2‐week period, the condition completely resolved. Very few vaccination‐related adverse events may manifest an unrecognized underlying autoimmune vasculopathy which may also require urgent management. As in this case, ocular adverse events, as highlighted, are highly associated with undiagnosed autoimmune diseases and therefore warrant careful assessment by clinicians.